Clinical Trial Update: Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bendamustine, prednisone, and Velcade for first-line treatment of symptomatic multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bendamustine (Bendamustine)
• PREDNISONE (Prednisone)
• Velcade (bortezomib)

Snippet

Sponsor: University Hospital Heidelberg | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED